PBAC's latest decision on Esomeprazole magnesium trihydrate: Recommended with restriction (2005). Considered for healing of peptic ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy.
PBAC outcome
Recommended with restriction
Restricted benefit
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2005
Submissions
1
2005 → 2005
Eligible population
patients with gastric ulcers not associated by H. pylori and treated with NSAIDs
Therapy area
Gastroenterology
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
ARD (absolute risk reduction)
Key trials
NEN-0005, NEN-0006, Yeomans 1998
Comparator
omeprazole
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as esomeprazole was deemed equi-effective to omeprazole